NCT02864953: A reported trial by Remedy Pharmaceuticals, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02864953 |
|---|---|
| Title | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 29, 2018 |
| Completion date | Aug. 18, 2023 |
| Required reporting date | Aug. 17, 2024, midnight |
| Actual reporting date | Dec. 19, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |